

THERAVANCE INC
Form 10-Q
August 04, 2010
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2010

OR

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission File Number: 0-30319

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Edgar Filing: THERAVANCE INC - Form 10-Q

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

94-3265960
(I.R.S. Employer
Identification No.)

901 Gateway Boulevard
South San Francisco, CA 94080

(Address of Principal Executive Offices including Zip Code)

(650) 808-6000

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of registrant's common stock outstanding on July 30, 2010 was 64,258,295

The number of shares of registrant's Class A common stock outstanding on July 30, 2010 was 9,401,499.

Table of Contents

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009 3

Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2010 and 2009 4

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009 5

Notes to Condensed Consolidated Financial Statements 6

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Item 3. Quantitative and Qualitative Disclosures About Market Risk 21

Item 4. Controls and Procedures 21

PART II. OTHER INFORMATION

Item 1A. Risk Factors 22

Item 6. Exhibits 36

Signatures 37

Exhibit Index 38

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Financial Statements****THERAVANCE, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS**

(In thousands, except per share data)

	June 30, 2010 (Unaudited)	December 31, 2009 *
Assets		
Current assets:		
Cash and cash equivalents	\$ 69,721	\$ 47,544
Marketable securities	140,972	107,846
Receivable from related party	33	274
Notes receivable	434	144
Prepaid and other current assets	5,063	6,234
Total current assets	216,223	162,042
Restricted cash	893	1,310
Property and equipment, net	11,049	12,927
Notes receivable	530	947
Other long-term assets	3,754	4,167
Total assets	\$ 232,449	\$ 181,393
Liabilities and stockholders' net capital deficiency		
Current liabilities:		
Accounts payable	\$ 1,749	\$ 1,792
Accrued personnel-related expenses	4,692	6,314
Accrued clinical and development expenses	2,231	1,805
Other accrued liabilities	4,335	5,129
Current portion of note payable and capital lease	195	184
Current portion of deferred revenue	22,802	23,722
Total current liabilities	36,004	38,946
Convertible subordinated notes	172,500	172,500
Deferred rent	1,782	851
Notes payable and capital lease	175	275
Deferred revenue	147,946	157,426
Other long-term liabilities		389
Commitments and contingencies		
Stockholders' net capital deficiency:		
Common stock, \$0.01 par value; 200,000 shares authorized; 64,242 and 54,830 shares issued and outstanding at June 30, 2010 and December 31, 2009, respectively	642	549

Edgar Filing: THERAVANCE INC - Form 10-Q

Class A Common Stock, \$0.01 par value, 30,000 shares authorized, 9,402 issued and outstanding at June 30, 2010 and December 31, 2009	94	94
Additional paid-in capital	1,033,427	927,082
Accumulated other comprehensive (loss) income	(26)	35
Accumulated deficit	(1,160,095)	(1,116,754)
Total stockholders' net capital deficiency	(125,958)	(188,994)
Total liabilities and stockholders' net capital deficiency	\$ 232,449	\$ 181,393

* Condensed consolidated balance sheet at December 31, 2009 has been derived from audited consolidated financial statements.

See accompanying notes to condensed consolidated financial statements.

Table of Contents**THERAVANCE, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share data)

(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Revenue (1)	\$ 6,264	\$ 5,493	\$ 11,979	\$ 15,037
Operating expenses:				
Research and development	18,705	20,020	39,057	39,577
General and administrative	6,991	6,796	13,467	13,848
Restructuring charges		30		1,313
Total operating expenses	25,696	26,846	52,524	54,738
Loss from operations	(19,432)	(21,353)	(40,545)	(39,701)
Interest and other income	134	1,172	229	1,819
Interest expense	(1,508)	(1,511)	(3,025)	(3,027)
Net loss	\$ (20,806)	\$ (21,692)	\$ (43,341)	\$ (40,909)
Basic and diluted net loss per share	\$ (0.28)	\$ (0.35)	\$ (0.63)	\$ (0.65)
Shares used in computing net loss per share	73,282	62,842	69,124	62,567

(1) Revenue includes amounts from GSK, a related party, of \$2,457 and \$2,708 for the three months ended June 30, 2010 and 2009, respectively, and \$4,913 and \$9,656 for the six months ended June 30, 2010 and 2009, respectively.

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THERAVANCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended June 30,	
	2010	2009
Cash flows from operating activities		
Net loss	\$ (43,341)	\$ (40,909)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	3,137	2,529
Stock-based compensation	9,820	10,387
Notes receivable	4	(23)
Changes in operating assets and liabilities:		
Receivables, prepaid and other current assets	1,205	545
Accounts payable and accrued liabilities	(232)	(1,092)
Accrued personnel-related expenses	(1,622)	(974)
Deferred rent	931	(280)
Deferred revenue	(10,400)	(4,038)
Other long-term liabilities	(389)	543
Net cash used in operating activities	(40,887)	(33,312)
Cash flows from investing activities		
Purchases of property and equipment	(133)	(359)
Purchases of marketable securities	(103,861)	(54,570)
Maturities of marketable securities	70,000	48,065
Release of restricted cash	417	2,500
Payments received on notes receivable	110	238
Net cash used in investing activities	(33,467)	(4,126)
Cash flows from financing activities		
Payments on notes payable and capital lease	(89)	(57)
Proceeds from issuances of common stock	96,620	6,313
Net cash provided by financing activities	96,531	6,256
Net increase (decrease) in cash and cash equivalents	22,177	(31,182)
Cash and cash equivalents at beginning of period	47,544	92,280
Cash and cash equivalents at end of period	\$ 69,721	\$ 61,098

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Theravance, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Theravance, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of the Company's management, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2010 or any other period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission (SEC) on February 26, 2010.

Use of Management's Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Inventory

Inventory is stated at the lower of cost or market and is included in prepaid and other current assets in the accompanying condensed consolidated balance sheets. Inventory consisted of \$2.5 million and \$3.4 million of VIBATIV finished goods, active pharmaceutical ingredient, or other commercial launch supplies as of June 30, 2010 and December 31, 2009, respectively. If Astellas Pharma Inc. (Astellas) decides not to purchase some or any of the remaining VIBATIV inventory, the Company will be required to expense a portion of or the entire remaining capitalized inventory.

Other-than-Temporary Impairment Assessment

The Company reviews its investment portfolio to identify and evaluate investments that have indications of possible impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, credit quality and the Company's conclusion that it does not intend to sell an impaired investment and is not more likely than not to be required to sell the security before it recovers its amortized cost basis. If the Company determines that the impairment of an investment is other-than-temporary, the investment is written down with a charge recorded in interest and other income.

Research and Development Costs

Research and development costs are expensed in the period that services are rendered or goods are received. Research and development costs consist of salaries and benefits, laboratory supplies and facility costs, as well as fees paid to third parties that conduct certain research and development activities on behalf of the Company, net of certain external development costs reimbursed by GlaxoSmithKline plc (GSK) and Astellas.

Fair Value of Stock-based Compensation Awards

The Company uses the fair value method of accounting for stock-based compensation arrangements. Stock-based compensation arrangements currently include stock options granted, restricted shares issued, restricted stock unit awards (RSUs) granted and performance-contingent RSUs granted under the 2004 Equity Incentive Plan and the 2008 New Employee Equity Incentive Plan and purchases of common stock by the Company's employees at a discount to the market price during offering periods under the Company's Employee Stock Purchase Plan (ESPP). The estimated fair value of stock options, restricted shares and RSUs is expensed on a straight-line basis over the expected term of the grant and the fair value of performance-contingent RSUs is expensed during the term of the award when the Company determines that it is probable that certain performance milestones will be met. Compensation expense for purchases under the ESPP is recognized based on the estimated fair value of the common stock during each offering period and the percentage of the purchase discount.

Table of Contents

Stock-based compensation expense for stock options and RSUs has been reduced for estimated forfeitures so that compensation expense is based on options and RSUs ultimately expected to vest. The Company's estimated annual forfeiture rates for stock options and RSUs are based on its historical forfeiture experience.

Recent Accounting Pronouncements

In January 2010, the Financial Accounting Standards Board issued guidance to amend the disclosure requirements related to recurring and nonrecurring fair value measurements. The guidance requires new disclosures on the transfers of assets and liabilities between Level 1 (quoted prices in active market for identical instruments) and Level 2 (significant other observable inputs) of the fair value measurement hierarchy, including the reasons and the timing of the transfers. Additionally, the guidance requires a roll forward of activities on purchases, sales, issuance, and settlements of the assets and liabilities measured using significant unobservable inputs (Level 3 fair value measurements). The guidance became effective for the Company with the reporting period beginning January 1, 2010, except for the disclosure on the roll forward activities for Level 3 fair value measurements, which will become effective for the Company with the reporting period beginning July 1, 2011. Adoption of this new guidance did not have a material impact on the Company's condensed consolidated financial statements.

2. Net Loss per Share

Basic net loss per share (basic EPS) is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase. Diluted net loss per share (diluted EPS) is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, plus any dilutive potential common shares. Diluted EPS is identical to basic EPS for all periods presented since potential common shares are excluded from the calculation, as their effect is anti-dilutive.

Using the treasury stock method, potential common shares that were excluded from the calculation of net loss per share are as follows:

(in thousands)	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Shares issuable upon the exercise of stock options	1,716	2,112	1,558	2,157
Shares issuable under restricted stock unit awards	466	305	324	291
Shares issuable upon the conversion of convertible debt	6,668	6,668	6,668	6,668

The calculation of basic and diluted EPS is as follows:

(in thousands, except for per share amounts)	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Basic and diluted:				
Net loss	\$ (20,806)	\$ (21,692)	\$ (43,341)	\$ (40,909)

Edgar Filing: THERAVANCE INC - Form 10-Q

Weighted average shares of common stock outstanding	73,339	62,919	69,181	62,644
Less: unvested restricted shares	(57)	(77)	(57)	(77)
Weighted average shares used in computing basic and diluted net loss per common share	73,282	62,842	69,124	62,567
Basic and diluted net loss per share	\$ (0.28)	\$ (0.35)	\$ (0.63)	\$ (0.65)

Table of Contents**3. Comprehensive Loss**

Comprehensive loss is comprised of net loss and changes in other comprehensive (loss) income, which consists of unrealized gains and losses on the Company's marketable securities. Comprehensive loss is as follows:

(in thousands)	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Net loss	\$ (20,806)	\$ (21,692)	\$ (43,341)	\$ (40,909)
Other comprehensive loss:				
Net unrealized loss on available-for-sale securities	(8)	(129)	(61)	(303)
Comprehensive loss	\$ (20,814)	\$ (21,821)	\$ (42,402)	\$ (41,212)

4. Restructuring Charges

In April 2008, in response to the completion of its Phase 3 telavancin development activities and to reduce its overall cash burn rate, the Company announced a plan to reduce its workforce by approximately 40% through layoffs from all departments throughout the organization. The Company incurred adjusted restructuring charges totaling \$5.4 million through 2008 and 2009 related to this reduction in force.

In February 2009, the Company entered into a sublease agreement with a third party to sublease excess space in a portion of one of its South San Francisco, CA buildings. The sublease has a 37 month term that began March 2009. For the six months ended June 30, 2009, the Company recorded a restructuring charge of \$1.3 million of which \$1.1 million represents the fair value of the Company's lease payments and expenses less sublease income through March 2012. As further described in Note 9, the Company entered into amendments to its South San Francisco, CA facility leases in June 2010. The amendments enabled the Company to reduce the accrual related to the sublet facilities by \$0.5 million for the three months ended June 30, 2010. The restructuring accrual related to excess facilities is recorded within other accrued liabilities on the Company's condensed consolidated balance sheets.

The following table summarizes the accrual balance and utilization by cost type for the restructuring for the six months ended June 30, 2010:

(in thousands)	Employee Severance and Benefits		Excess Facilities	
Balance as of December 31, 2009	\$	116	\$	694
Cash payments		(116)		(136)*
Adjustment				(504)
Balance as of June 30, 2010	\$		\$	54

* Includes cash payments less sublease payments received

Edgar Filing: THERAVANCE INC - Form 10-Q

To date, the Company has incurred cumulative adjusted restructuring charges of \$6.7 million relating to the actions taken in April 2008 and February 2009. The Company does not anticipate incurring additional restructuring charges from these actions.

5. Collaboration and Licensing Agreements

2005 License, Development and Commercialization Agreement with Astellas

In November 2005, the Company entered into a collaboration arrangement with Astellas for the development and commercialization of telavancin. In July 2006, Japan was added to the collaboration, thereby giving Astellas worldwide rights to this medicine. Through June 30, 2010, the Company has received \$191.0 million in upfront, milestone and other fees from Astellas. The Company is eligible to receive up to an additional \$30.0 million in remaining milestone payments related to regulatory approvals in various regions of the world. The Company records these payments as deferred revenue and is amortizing them ratably over its estimated period of performance (development and commercialization period).

Table of Contents

Under this arrangement, the Company is responsible for substantially all costs to develop and obtain U.S. regulatory approval for telavancin for complicated skin and skin structure infections (cSSSI) and nosocomial pneumonia (NP) and Astellas is responsible for substantially all other costs associated with commercialization and further development of telavancin. The Company is entitled to receive royalties on global net sales of VIBATIV by Astellas that, on a percentage basis, range from the high teens to the upper twenties depending on sales volume. The following table discloses net revenue under this collaboration agreement:

(in thousands)	Three Months Ended June 30,			Six Months Ended June 30,		
	2010	2009	2009	2010	2009	2009
Amortization of deferred revenue	\$ 3,244	\$ 2,785	\$ 2,785	\$ 6,487	\$ 5,380	\$ 5,380
Royalties from net sales of VIBATIV	114			124		
Proceeds from VIBATIV delivered to Astellas	1,393			1,393		
Cost of VIBATIV delivered to Astellas	(943)			(943)		
Net Astellas collaboration revenue	\$ 3,808	\$ 2,785	\$ 2,785	\$ 7,061	\$ 5,380	\$ 5,380

RELOVAIR™ Program with GSK

In November 2002, the Company entered into its long-acting beta2 agonist (LABA) collaboration with GSK (the RELOVAIR program) to develop and commercialize a LABA product candidate both as a single-agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long-acting muscarinic antagonist (LAMA) for COPD.

In connection with the RELOVAIR program, in 2002 the Company received from GSK an upfront payment of \$10.0 million and sold to an affiliate of GSK shares of the Company's Series E Preferred Stock for an aggregate purchase price of \$40.0 million. In addition, the Company was eligible to receive up to \$495.0 million in development, approval, launch and sales milestones and royalties on the sales of any product resulting from this program. Through June 30, 2010, the Company has received a total of \$60.0 million in upfront and development milestone payments. GSK has determined to focus the collaboration's resources on the development of the lead LABA, GW642444, a GSK-discovered compound, together with GSK's ICS, fluticasone furoate. Accordingly, the Company does not expect to receive any further milestone payments from the RELOVAIR program. In the event that a LABA product candidate discovered by GSK is successfully developed and commercialized, the Company would be obligated to make milestone payments to GSK which could total as much as \$220.0 million if both a single-agent and a combination product were launched in multiple regions of the world. Based on available information, the Company does not estimate that a significant portion of these potential milestone payments to GSK are likely to be made in the next two years. Moreover, the Company is entitled to receive the same royalties on sales of medicines from the RELOVAIR program, regardless of whether the product candidate originated with Theravance or with GSK. The Company is entitled to receive royalties of 15% on the first \$3.0 billion of annual global net sales, and 5% on annual global net sales above \$3.0 billion, for approved single-agent LABA and combination LABA-ICS medicines. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the RELOVAIR program, such as a combination LABA/LAMA medicine, which are launched after a LABA/ICS combination medicine, royalties are upward tiering and range from the mid-single digits to 10%. However, if GSK is not selling a LABA/ICS combination product at the time that the first other LABA combination is launched, then the royalties described above for the LABA/ICS combination medicine are applicable.

The Company recorded the initial cash payment and subsequent milestone payments as deferred revenue and is amortizing them ratably over its estimated period of performance (the product development period). Collaboration revenue from GSK under this agreement was \$1.3 million in each of the three months ended June 30, 2010 and 2009 and \$2.5 million in each of the six months ended June 30, 2010 and 2009, respectively.

2004 Strategic Alliance with GSK

In March 2004, the Company entered into its strategic alliance with GSK. Under this alliance, GSK received an option to license exclusive development and commercialization rights to product candidates from all of the Company's full drug discovery programs initiated prior to September 1, 2007, on pre-determined terms and on an exclusive, worldwide basis. Under the terms of the strategic alliance, GSK has only one opportunity to license each of the Company's programs. Upon GSK's decision to license a program, GSK is responsible for funding all future development, manufacturing and commercialization activities for product candidates in that program. In addition, GSK is obligated to use diligent efforts to develop and commercialize product candidates from any program that it licenses. Consistent with the Company's strategy, it is obligated at its sole cost to discover two structurally different product candidates for any programs that are licensed by GSK under the alliance. If these programs are successfully advanced through development by GSK, the Company is entitled to receive clinical, regulatory and commercial milestone payments and royalties on any sales of medicines developed from these programs. For product candidates licensed to date under this agreement, the royalty structure for a product containing one of its compounds as a single active ingredient would result in an average percentage royalty rate in the low double digits. If a product is successfully commercialized, in addition to any royalty revenue that the Company receives, the total upfront and milestone payments that it could receive in any given program that GSK licenses range from \$130.0 million to \$162.0 million for programs with single-agent medicines and up to \$252.0 million for programs with both a single-agent and a combination medicine. If GSK chooses not to license a program, the Company retains all rights to the program and may

Table of Contents

continue the program alone or with a third party. To date, GSK has licensed the Company's two COPD programs: long-acting muscarinic antagonist (LAMA) and bifunctional muscarinic antagonist-beta2 agonist (MABA). The Company received \$5.0 million payments from GSK in connection with its license of each of the Company's LAMA and MABA programs in August 2004 and March 2005, respectively. GSK has chosen not to license the Company's bacterial infections program, anesthesia program or 5-HT4 program.

In connection with the strategic alliance with GSK, the Company received from GSK a payment of \$20.0 million. This payment is being amortized over the initial performance period during which GSK may exercise its right to license certain of the Company's programs under the agreement. In connection with the strategic alliance, the Company recognized \$0.7 million in revenue for each of the three months ended June 30, 2010 and 2009 and \$1.4 million for each of the six months ended June 30, 2010 and 2009. In addition, in May 2004, GSK purchased through an affiliate 6,387,096 shares of the Company's Class A common stock for an aggregate purchase price of \$108.9 million.

Through June 30, 2010, the Company has received \$46.0 million in upfront and milestone payments from GSK relating to the strategic alliance agreement. In addition, pursuant to a partial exercise of its rights under the governance agreement, upon the closing of the Company's initial public offering on October 8, 2004, GSK purchased through an affiliate an additional 433,757 shares of Class A common stock for \$6.9 million.

In August 2004, GSK exercised its right to license the Company's LAMA program pursuant to the terms of the strategic alliance. The Company received a \$5.0 million payment from GSK in connection with its licensing of the Company's LAMA program. In June 2005, the Company received a milestone payment from GSK of \$3.0 million related to clinical progress of the Company's product candidate. These payments were amortized ratably over the estimated period of performance (the product development period) until March 2009, when the Company recognized the remaining \$4.2 million of deferred revenue related to the LAMA program as a result of the program being returned to the Company from GSK.

In March 2005, GSK exercised its right to license the Company's MABA program pursuant to the terms of the strategic alliance. The Company received a \$5.0 million payment from GSK in connection with the license of the Company's MABA program. Through June 30, 2010, the Company received milestone payments from GSK of \$13.0 million related to clinical progress of the Company's product candidate. These payments are being amortized ratably over the estimated period of performance (the product development period). The Company recognized \$0.5 million and \$0.8 million in revenue related to the MABA program for the three months ended June 30, 2010 and 2009, respectively, and \$1.0 million and \$1.5 million for the six months ended June 30, 2010 and 2009, respectively.

6. Marketable Securities

The Company manages, monitors and measures its investments in highly liquid investment-grade securities by major security type. The following is a summary of the Company's cash equivalents, marketable securities and restricted cash by major security type at June 30, 2010 and December 31, 2009:

(in thousands)	June 30, 2010			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
U.S. government securities	\$ 39,986	\$ 29	\$	\$ 40,015

Edgar Filing: THERAVANCE INC - Form 10-Q

U.S. government agency securities	49,832	22	(1)	49,853
U.S. corporate notes	28,701	2	(78)	28,625
U.S. commercial paper	39,813			39,813
Money market funds	49,664			49,664
Total	207,996	53	(79)	207,970
Less amounts classified as cash equivalents	(66,105)			(66,105)
Less amounts classified as restricted cash	(893)			(893)
Amounts classified as marketable securities	\$ 140,998	\$ 53	\$ (79)	\$ 140,972

Table of Contents

(in thousands)	December 31, 2009			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
U.S. government securities	\$ 45,123	\$ 27	\$ (5)	\$ 45,145
U.S. government agency securities	18,032	10		18,042
U.S. corporate notes	11,181	8	(5)	11,184
U.S. commercial paper	43,473	1		43,474
Money market funds	35,425			35,425
Total	153,234	46	(10)	153,270
Less amounts classified as cash equivalents	(44,114)			(44,114)
Less amounts classified as restricted cash	(1,310)			(1,310)
Amounts classified as marketable securities	\$ 107,810	\$ 46	\$ (10)	\$ 107,846

The estimated fair value amounts were determined using available market information. At June 30, 2010, 100% of marketable securities have contractual maturities within twelve months and the average duration of marketable securities was approximately six months. The Company does not intend to sell the investments which are in an unrealized loss position and it is unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company has determined that the gross unrealized losses on its marketable securities at June 30, 2010 were temporary in nature. All marketable securities with unrealized losses have been in a loss position for less than twelve months.

7. Fair Value Measurements

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The Company's valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect the Company's market assumptions.

The Company classifies these inputs into the following hierarchy:

Level 1 Inputs Quoted prices for identical instruments in active markets

Level 2 Inputs Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable

Level 3 Inputs Unobservable inputs and little, if any, market activity for the assets

Edgar Filing: THERAVANCE INC - Form 10-Q

The Company's assets and liabilities that are measured at fair value are based on one or more of the three following valuation techniques:

Market approach Prices and other relevant information generated by market transactions involving identical or comparable assets

Cost approach Amount that would be required to replace the service capacity of an asset

Income approach Techniques to convert future amounts to a single present amount based on expectations

Table of Contents

The fair values of the Company's financial assets were as follows at June 30, 2010 and December 31, 2009:

(in thousands)	Fair Value Measurements at Reporting Date Using				Total
	Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3		
U.S. government securities	\$ 35,015	\$ 5,000	\$	\$	40,015
U.S. government agency securities	41,241	8,612			49,853
U.S. corporate notes	24,869	3,756			28,625
U.S. commercial paper		39,813			39,813
Money market funds	49,664				49,664
Total	\$ 150,789	\$ 57,181	\$	\$	207,970

(in thousands)	December 31, 2009 Fair Value Measurements at Reporting Date Using				Total
	Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3		
U.S. government securities	\$ 45,145	\$	\$	\$	45,145
U.S. government agency securities	18,042				18,042
U.S. corporate notes	1,020	10,164			11,184
U.S. commercial paper		43,474			43,474
Money market funds	35,425				35,425
Total	\$ 99,632	\$ 53,638	\$	\$	153,270

8. Convertible Subordinated Notes

On January 23, 2008, the Company closed an underwritten public offering of \$172.5 million aggregate principal amount of unsecured convertible subordinated notes that will mature on January 15, 2015. The financing raised proceeds, net of issuance costs, of \$166.7 million. The notes bear interest at the rate of 3.0% per year, which is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2008. The notes are convertible, at the option of the holder, into shares of the Company's common stock at an initial conversion rate of 38.6548 shares per \$1,000 principal amount of the notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately \$25.87 per share. The debt issuance costs, which are included in other long-term assets, are being amortized on a straight-line basis over the life of the notes.

Holders of the notes will be able to require the Company to repurchase some or all of their notes upon the occurrence of a fundamental change (as defined) at 100% of the principal amount of the notes being repurchased plus accrued and unpaid interest. The Company may not redeem the notes prior to January 15, 2012. On or after January 15, 2012 and prior to the maturity date, the Company, upon notice of redemption, may redeem for cash all or part of the notes if the last reported sale price of its common stock has been greater than or equal to 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period prior to the date on which it provides notice of redemption. The redemption price will equal 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest up to but excluding the redemption date.

Edgar Filing: THERAVANCE INC - Form 10-Q

The following table presents the carrying values and estimated fair values for the notes as of June 30, 2010 and December 31, 2009. The estimated fair value amounts were determined using available market information.

(in thousands)	June 30, 2010		December 31, 2009	
	Carrying value	Estimated fair value	Carrying value	Estimated fair value
Convertible subordinated notes	\$ 172,500	\$ 147,327	\$ 172,500	\$ 137,784

9. Operating Lease and Sublease

The Company entered into amendments to its South San Francisco, CA facility leases in June 2010. These amendments extend the lease terms through May 2020 and the Company may extend the terms for two additional five-year periods. The leases are for two buildings of approximately 110,000 and 60,000 square feet.

Table of Contents

Under the amendments, unused portions of a tenant improvement allowance can be used to reduce base rent up to a limit. Without considering such reductions, at June 30, 2010, future commitments under the amended noncancelable operating leases are as follows:

(in thousands)

Years ending December 31:		
Remainder of 2010	\$	2,312
2011		4,466
2012		5,429
2013		5,029
2014		4,860
Thereafter		28,966
Total	\$	51,062

10. Stock-Based Compensation

2008 New Employee Equity Incentive Plan

For the six months ended June 30, 2010, the Company granted stock options to purchase 110,000 shares at a weighted average exercise price of \$10.95 per share under the 2008 Plan. For the six months ended June 30, 2009, the Company granted stock options to purchase 133,000 shares at a weighted average exercise price of \$14.83 per share and granted 10,000 RSUs with a weighted-average fair value of \$14.31 per share under the 2008 Plan. With stockholders' approval of the amendment and restatement of the 2004 Plan in April 2010, no further equity awards will be issued under the 2008 Plan.

2004 Equity Incentive Plan

For the six months ended June 30, 2010, the Company granted stock options to purchase 143,750 shares at a weighted average exercise price of \$16.37 per share and granted 940,042 RSUs and 210,000 performance RSUs with a weighted-average fair value of \$10.47 per share and \$10.12 per share, respectively, under the 2004 Plan. For the six months ended June 30, 2009, the Company granted 928,911 RSUs with a weighted-average fair value of \$14.66 per share and 42,000 stock options with a weighted-average exercise price of \$14.98 per share under the 2004 Plan. As of June 30, 2010, there were 6,667,142 shares remaining available for issuance under the 2004 Plan. On April 27, 2010, an amendment and restatement of the 2004 Plan was approved by the Company's stockholders to, among other things, reserve additional shares of common stock for issuance thereunder.

The following table summarizes equity award activity under the 2008 Plan and the 2004 Plan and related information:

(in thousands, except per share data)	Number of Shares Subject to Outstanding	Weighted-Average Exercise Price per Share	Number of Shares Subject to Outstanding	Weighted-Average Fair Value per Share
---------------------------------------	---	---	---	---------------------------------------

Edgar Filing: THERAVANCE INC - Form 10-Q

	Options		RSUs	
Balance at December 31, 2009	8,414	\$ 16.63	2,042	\$ 14.15
Granted	110	10.95	1,087	10.15
Exercised	(86)	7.68		
Released			(122)	14.37
Forfeited	(72)	29.39	(7)	14.24
Balance at March 31, 2010	8,366	16.54	3,000	15.72
Granted	144	16.37	63	14.79
Exercised	(225)	7.23		
Released			(174)	13.04
Forfeited	(82)	21.35	(569)	28.40
Balance at June 30, 2010	8,203	\$ 16.75	2,320	